The Role of Hypoxia-inducible Factor-1 in Bladder Cancer

Jiagui Chai; Sifan Yin; Wenbo Feng; Tao Zhang; Changxing Ke

doi:10.2174/1566524023666230720163448

The Role of Hypoxia-inducible Factor-1 in Bladder Cancer

Curr Mol Med. 2023 Jul 20. doi: 10.2174/1566524023666230720163448. Online ahead of print.

Authors

Jiagui Chai¹, Sifan Yin¹, Wenbo Feng¹, Tao Zhang¹, Changxing Ke^{1

2}

Affiliations

¹ Department of Urology, the Second Affiliated Hospital of Kunming Medical University, Kunming 650106, China.
² Yunnan Institute of Urology, Kunming 650106, China.

PMID: 37475553
DOI: 10.2174/1566524023666230720163448

Abstract

Bladder cancer (BC) is one of the most common malignant tumors worldwide and poses a significant hazard to human health. During the development of BC, hypoxia plays a crucial role. Hypoxia-inducible factor (HIF) is a key transcription factor for hypoxic adaptation, which regulates the transcription of various genes, including inflammation, angiogenesis, and glycolytic metabolism. Recent studies have shown the precise role of HIF in various biological behaviors of BC. More importantly, a new antitumor medication targeting HIF-2 has been used to treat renal cancer. However, therapies targeting HIF-1 in BC have not yet been developed. In this review, we discussed how HIF-1 is expressed and affects the growth, metastasis, and angiogenesis of BC. At the same time, we investigated several HIF-1 inhibitors that provide new perspectives for targeting HIF-1.

Keywords: Angiogenesis; Bladder cancer; Drug resistance; Glucose metabolism; HIF-1; Metastasis; Proliferation; Treatment..